U.S., July 25 -- ClinicalTrials.gov registry received information related to the study (NCT07082270) titled 'Selvigaltin With Standard of Care Treatment for the Treatment of Relapsed/Refractory Multiple Myeloma' on July 16.
Brief Summary: This phase I trial studies the side effects and best dose of selvigaltin when given together with standard of care treatment (daratumumab-hyaluronidase, carfilzomib, dexamethasone) in treating patients with multiple myeloma that has come back after a period of improvement (relapsed) or that does not respond to treatment (refractory). Selvigaltin works by blocking the activity of a protein called galectin-3. Galectin-3 is involved in various cellular processes, including inflammation and tissue scarring, w...